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TEN- toxic epidermal necrolysis
Introduction
General Microbiology: Staphylococci are hardy
Gram-positive cocci found as bacterial pathogens or
commensal organisms in both humans and animals.
These organisms are resistant to harsh conditions and
can be recovered from non-physiologic environments up
to months after inoculation. They grow easily under
numerous conditions and are classified based on coagu-
lase activity. Coagulase positive strains are classified as
Staphylococcus aureus. Approximately 35% of the
general population are commensal nasal carriers and
most newborns will be colonized within the first week of
life (Dancer and Noble, 1991). Of the staphylococci, S.
aureus is the most significant pathogen causing both
human and animal diseases. S. aureus causes a wide
variety of infections acquired in both the community and
hospital settings. It is the most common cause of
pyogenic infections of the skin. A variety of predisposing
factors may lead to more serious infections such as
conjunctivitis, pneumonia, septicemia, osteomyelitis,
septic arthritis, empyema, meningitis, pericarditis or
endocarditis. Diseases caused by S. aureus can be the
result of direct tissue invasion or due to the action of a
variety of exotoxins released by the bacteria (Iandolo,
1989; Marrack and Kappler, 1990). S. aureus strains
capable of causing disease express a wide variety of
virulence factors including exported toxins (exotoxins),
cell surface molecules associated with adhesion and
multiple antibiotic resistances including methicillin and
vancomycin resistance (Centers for Disease Control and
Prevention, 1997; 2000a; 2000b), all contributing to the
pathogenicity of these organisms. A minimum of 34
different extracellular proteins are produced by S.
aureus, and many of these have defined roles in the
pathogenesis of their associated diseases (Iandolo,
1989). Infectious conditions caused by these organisms
can be divided into three major categories; (i) superficial
skin infections, skin abcesses and wound infections
including bullous impetigo (BI) and furuncles, (ii)
systemic or infections of deep seeded tissues including
osteomyelitis, endocarditis, pneumonia and sepsis, and
(iii) conditions caused by intoxication with one of the
excreted toxins. Among the conditions caused by intoxi-
cation with an exotoxin are toxic shock syndrome caused
by toxic shock syndrome toxin (TSST-1) (Bloster-Hauta-
maa et al, 1986), staphylococcal food poisoning caused
by the staphylococcal enterotoxins (SE) (Bergdoll, 1972;
Bergdoll, 1983; Bergdoll et al, 1981) and staphylococcal
scalded skin syndrome (SSSS) mediated by the exfolia-
tive toxins (ETs), primarily ETA and ETB (Arbuthnott et
al, 1972). This discussion will focus on the exfoliative
toxins of S. aureus and the mechanism by which they
cause disease in humans. 
General characteristics of the exfoliative toxins.
There are two major biologically and serologically
distinct S. aureus ET isoforms that are primarily respon-
sible for the skin manifestations of SSSS and BI in
humans (Wiley and Rogolsky, 1977) ETA and ETB. Five
percent of clinical S. aureus isolates produce either ETA,
ETB or both toxins (Piemont et al, 1984) and there are
reported geographic differences in the prevalence of the
particular toxins that are expressed. In North America,
Europe and Africa ETA is the predominant ET (Adesiyun
et al, 1991; Ladhani, 2001), in contrast ETB has been
reported to be more common in Japan (Kondo et al,
1975). These toxins exhibit exquisite species specificity,
being active in humans, mice, monkeys and hamsters
Editor: Alan N. Moshell, M.D.
Published by the
Progress in
Dermatology
The production of this issue of Progress in Dermatology
has been underwritten by Galderma Laboratories, L.P.
©2003 Dermatology Foundation, 1560 Sherman Avenue, Evanston, Illinois 60201
To cite this article: JID 122:1070–1077, 2004
1070
but not in rats, rabbits, dogs, hedgehogs, voles, guinea
pigs, chickens or frogs (Bailey et al, 1995; Elias et al,
1975; Ladhani et al, 1999). 
Both ETA and ETB have been cloned and their resul-
tant protein products characterized (Lee et al, 1987;
O’Toole and Foster, 1987). The primary human active
ETs, ETA and ETB, share significant amino acid identity
with each other and have similar biophysical properties
(Bailey et al, 1980; Lee et al, 1987; O’Toole and Foster,
1987). A comparison of these toxins is shown in Table 1.
ETA is a very stable protein that is resistant to extreme
heat while ETB is heat sensitive. Both ETA and ETB
share amino acid identity with staphylococcal V8
protease (glutamyl endopeptidase I), a well character-
ized general serine protease of S. aureus (26% with ETA
and 31% with ETB). Most significantly, this identity
includes the key amino acid residues of the V8 protease
active site, serine-histidine-aspartate. This catalytic triad
is highly conserved and forms the active site of trypsin-
like serine proteases (Dancer et al, 1990). The X-ray
crystal structures of both of these toxins have been
determined (Cavarelli et al, 1997; Papageorgiou et al,
1999; Vath et al, 1999; Vath et al, 1997). These three-
dimensional structures show marked similarity with each
other and V8 protease demonstrating that the ETs are
members of the trypsin-like serine protease family, but
do have some significant differences at the amino- and
carboxyl-termini.
Recently a new potential human active exfoliative
toxin, ETD, was identified from an isolate of S. aureus
taken from a wound site. It was initially identified as an
open reading frame which had significant homology to
the known ETs (Yamaguchi et al, 2002) but has also
been associated with a clinical isolate from a patient with
BI (Yamaguchi et al, 2002; Yamaguchi et al, 2002). ETD
expressed as a recombinant protein product demon-
strated specific protease activity in the neonatal mouse
model and exhibits cleavage of recombinant mouse or
human Dsg1 which is indistinguishable from that of ETA
by Western blot analysis (Hanakawa et al, 2002). It was
further shown to be serologically distinct from ETA and
ETB. A fourth potential human active ET produced from
S. aureus, ETC, was isolated from a horse infection and
was shown to have activity in the neonatal mouse model
(Sato et al, 1994); however, it has not been associated
with human disease. The clinical significance of either
ETD or ETC has not been established. Other similar
exfoliative toxins made by S. hyicus, (ShETA, ShETB
and ShETC) have also been identified and partially
characterized (Anderson, 1998). These toxins have been
associated with comparable skin diseases in different
animal populations but are likewise not associated with
disease in humans. 
The ETs, like most staphylococcal proteins associat-
ed with virulence, are encoded on mobile genetic
elements (Novick, 2003) allowing for horizontal transfer
of these virulence factors. The gene encoding ETA is
located on the bacterial chromosome within a 43 kb
temperate phage, ETA (Yamaguchi et al, 2000), that
was recently shown to be capable of transducing a toxin
negative S. aureus strain to positive. ETB is encoded on
approximately 38.2-38.5 kb plasmids (Lee et al, 1987;
Yamaguchi et al, 2001). ETD was identified within a
pathogenicity island which also encodes EDIN-B
(Yamaguchi et al, 2002). Pathogenicity islands are
varied sized segments of potentially mobile DNA that
encode virulence associated genes (Kaper and Hacker,
1999). These islands have been described for numerous
types of bacteria and at least three different types of
pathogenicity islands have been reported in staphylo-
coccal species (Kuroda et al, 2001). Also like most
staphylococcal virulence factors, the ETs are regulated
by the staphylococcal accessory gene regulator locus,
agr locus (Ji et al, 1995; Novick, 2003). This locus
encodes a two-component regulatory system that coordi-
nates the expression of specific virulence factors not
required for bacterial viability, including the exotoxins.
The ETs have a strong association with a particular agr
group, agr group IV, (Jarraud et al, 2000) but the clinical
significance of this association remains to be estab-
lished.
Clincal conditions caused by the exfoliative
toxin producing S. aureus.
Staphylococcal scalded skin syndrome and
Bullous impetigo. Staphylococcal scalded skin
syndrome (SSSS) is an exfoliative dermatitis mediated
by infection with S. aureus capable of producing one or
both of the exfoliative toxins ETA or ETB. This condition
is well described and discussed in several recent
reviews (Ladhani, 2001; Ladhani and Evans, 1998;
Prevost et al, 2003). It is typically a condition of infants
and young children, although it may also affect adults
(Cribier et al, 1994; Gemmell, 1995). SSSS is character-
ized by the separation of extended areas of
the upper epidermis specifically at the level
of the stratum granulosum by disruption of
the desmosomes after specific cleavage of
desmoglein 1 (Amagai et al, 2000; Amagai
et al, 2002). The condition can initiate with
fever and erythema, followed by a positive
Nikolsky’s sign and progress to the forma-
tion of large bullae and exfoliation of exten-
sive areas of the upper epidermis of the
skin. In SSSS this exfoliation occurs at a site
that is separate from that of the infection.
The infecting bacteria produce the exotoxin
and release it into the blood stream where it
makes it’s way to the skin and causes exfoli-
ation/epidermolysis. Infections that result in
SSSS may be as serious as pneumonia or
sepsis in adults, or as trivial as otitis media
or uncomplicated conjunctivitis in children.*Predicted number of amino acids after removal of signal sequence.
Percent Amino Acid Identity
ETA ETB ETD
ETA 100 40 40
ETB 100 59
ETD 100
Toxin Size Molecular weight Accession #
ETA 242 aa 26.9 kDa PO9331
ETB 246 aa 27.3 kDa AAA26628
ETD 244 aa* 27.2 kDa AB036767
Table 1. Comparison of human active exfoliative toxins
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In infants and children the syndrome is usually associat-
ed with a trivial infective focus, 3% mortality with appro-
priate antibiotic therapy, and the patients are rarely
bacteremic (Gemmell, 1995). Mortality in children is
usually associated with secondary infections and other
complications from the loss of the upper epidermis of the
skin or failure to appropriately treat the underlying infec-
tion. However, hospital nursery outbreaks continue to be
reported and are becoming increasingly associated with
drug resistant strains of S. aureus (MRSA) (Cribier et al,
1994; Ito et al, 2002; Mackenzie et al, 1995). 
In contrast, the syndrome in adults is usually associ-
ated with a chronic underlying medical condition. It is
most often associated with old age, an immunocompro-
mised state, renal deficiencies or diabetes mellitus
(Cribier et al, 1994) but has been described in healthy
adults (Oyake et al, 2001). There is often bacteremia and
a greater than 50% mortality rate even with appropriate
antibiotic therapy (Cribier et al, 1994). The increased
mortality rate is likely heavily contributed to by the under-
lying medical condition that might have predisposed the
adult to infection with S. aureus or to the affects of the
exfoliative toxin itself. When SSSS has been reported in
healthy adults there is usually insignificant morbidity or
mortality (Oyake et al, 2001). 
In SSSS the bullous fluid is characteristically a sterile
transudate. There is no inflammatory cell infiltration
associated with the bullous lesions or exfoliated areas
unless or until there is a secondary infection at that
location. This is in contrast to bullous impetigo, which is
a localized skin infection with exfoliative toxin producing
S. aureus. In BI there are bullous lesions with purulent
exudates, local signs of inflammation, inflammatory cell
infiltrates and necrosis, and S. aureus can usually be
isolated from the lesions. Recently Gravet and cowork-
ers showed that ET positive strains of S. aureus isolated
from patients with impetigo were associated with the
leukotoxin, LukE-LukD, in 78% of cases studied (Gravet
et al, 2001). These pore forming toxins may contribute to
the local inflammation and necrosis seen in BI, but their
role in the condition has not been clearly established. To
date, no association has been recognized with S. aureus
strains isolated from clinical cases of SSSS and the
leukotoxin, LukE-LukD. Koning and coworkers have also
shown an association of ETB producing stains with P-V
leukocidin, a toxin that is linked to necrotic pneumonias
(Gillet et al, 2002), and the multidrug resistant plasmid
pSK41 (Koning et al, 2003). They report that this combi-
nation of virulence factors contributes to the severity of
nonbullous impetigo. However no association of these
factors with BI or SSSS has been demonstrated. The
role of the exfoliative toxins in the pathogenesis of
bullous impetigo clearly appears to be the enhancement
of local spread of the organism in a relatively protected
plane, just under the stratum corneum in the upper
epidermis, thus allowing for a successful infection by the
organism. The presence of additional toxins such as the
leukocidins or other potential virulence factors may
augment this process and contribute to a successful
infection by thwarting the host’s immune response. In
contrast, the role of these toxins to promote bacterial
survival and enhance their pathogenicity in SSSS is not
so clear and warrants additional research. For a more
extensive review of SSSS see references (Ladhani and
Evans, 1998; Ladhani et al, 1999). 
In addition to the associations with the leukotoxins
LukE-LukD and P-V luekocidin, and the multidrug resis-
tance plasmid pKS41 (Gravet et al, 2001; Koning et al,
2003), there are further reports linking the ETs with other
virulence factors. ETD is also clonally linked to EDIN-B
(C3stau) (Yamaguchi et al, 2002) and ETB has been
linked to EDIN-C (Yamaguchi et al, 2001). There are
three EDIN isoforms produced by S. aureus. EDIN-A
was the first discovered as an inhibitor of morphological
differentiation of epidermal keratinocytes in vitro and
thus called epidermal cell differentiation inhibitor (EDIN)
(Sugai et al, 1992). It is now accepted that the EDINs
belong to the C3 family of bacterial Rho-specific mono-
ADP-ribosyltransferases that specifically modify eukary-
otic small GTP-binding proteins belonging to the Rho
family (Sugai et al, 1992). Rho GTPases are central
regulators of the eukaryotic actin cytoskeleton and their
inactivation blocks important cellular functions including
differentiation, chemotaxis, phagocytosis and oxidative
burst (Aktories et al, 2000). The clinical significance of
the association of the EDINs with the ETs and the role of
EDINs in the pathogenesis of S. aureus are not clear.
Likewise the role of ETD is unclear as it has only been
rarely isolated (1 in 88 isolates) from S. aureus obtained
from impetigo patients (Yamaguchi et al, 2002;
Yamaguchi et al, 2002), but warrants further investigation.
The characteristic separation of the epidermis at the
stratum granulosum seen in SSSS is also demonstrated
in the neonatal mouse model (Melish and Glasgow,
1970) Figure 1. Animal models of SSSS show identical
response to either of the purified ETs. This cleavage is
associated with a disruption of the desmosomes, with
the surrounding cells remaining intact. The mechanism
by which these toxins cause exfoliation is now known to
involve cleavage of desmoglein 1 (Dsg1), a desmosomal
protein member of the cadherin family of cell adhesion
molecules. This is accomplished by a unique serine
protease activity of the exfoliative toxins acting at a
specific extracellular site on Dsg1, as recently described
(Amagai et al, 2000). Dsg1 is the predominant cell-cell
adhesion molecule in the upper epidermis where the
separation occurs. Dsg1 amino acid sequences are
highly conserved among mammalian species and share
a high percentage of identity (Koch and Franke, 1994;
Nilles et al, 1991). In other studies ETA has been shown
to cleave - and -melanocyte stimulating hormones
after a lengthy incubation period (Rago et al, 2000);
however, it is unclear how this might result in or
contribute to SSSS or BI. Also, other investigators study-
ing ETB have purified a distinct 20 kDa protease from a
supernatant of preparations of neonatal mouse epider-
mis treated with ETB which was able to reproduce
epidermolysis similar to that of SSSS when injected into
neonatal mice (Ninomiya et al, 2000). These results
would suggest the presence of an additional target for
the ETB versus ETA, as Dsg1 has been shown to be
Figure 1. Panel A: normal newborn Balb/c mouse skin; Panel
B, Newborn Balb/c mouse injected with purified ETA.
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cleaved by both ETB and ETA (Amagai et al, 2000;
Amagai et al, 2002).
Relative protection of healthy adults against the
effects of the toxins. SSSS and BI are primarily
diseases of infants and children and SSSS only rarely
develops in adults (Cribier et al, 1994; Gemmell, 1995).
In the mouse model of SSSS it was originally shown that
newborn mice would exfoliate in response to injection
with ET producing S. aureus, but that mice greater than
7 days old would not exfoliate. A time course of suscep-
tibility of newborn mice to these toxins was recently
generated and showed that until day 7 of life, mice were
sensitive to the affects of a single injection of a low dose
of the toxin. However, after 8 days of life there is a
dramatic decrease in response to these exotoxins such
that these mice failed to respond to even 10 times the
dose that caused exfoliation in the population 24 hours
prior (Plano et al, 2001). The mechanism of the relative
protection in healthy adults who are exposed to the ETs
is not completely understood but likely is a multifactorial
process. It is known that in mice the adaptive immune
response matures within the same time frame as they
developed resistance to ETA and ETB (Adkins, 1999). It
has been shown that over time healthy humans will
produce antibodies that recognize the exfoliative toxins.
In one study, more than 50% of persons over the age of
10 years had antibodies that recognize ETA (Melish et
al, 1981), however it was undetermined whether these
were specific antibodies raised against ETA or against a
cross reacting material. The fact that only about 5% of all
clinical S. aureus isolates are capable of producing ETA
argues against these being specific antibodies. In a
recent study conducted in our labs we investigated the
role of the adaptive immune response in the protection of
adult mice and concluded that it does not play a primary
role in defense of 10 day old mice against the effects of
the ETs (Plano et al, 2001). The role of the adaptive
immune response was investigated using two immune
compromised mouse populations: (i) mice deficient in T
cells (BALB/c mice thymectomized as newborns and
allowed to grow to adulthood) and (ii) mice deficient in
both T and B cell (CB-17 SCID mice) and therefore
unable to produce antibodies. Neither of these immun-
odeficient populations of mice was affected by exposure
to the exotoxin. Furthermore, attempts to protect
newborn mice from the effects of the ETs with intra-
venous injections of normal adult mouse spleen cells
either prior to or at the time of exposure to the ETs failed.
From these data it was concluded that although clearly
the adaptive immune response can play a role in protect-
ing against the exotoxins once specific antibodies are
made, it does not play a primary role in the protection of
adult mice from the effects of these toxins.
Rapid clearance of the ETs from the serum was
however shown to play a key role in protection of adult
mice (Plano et al, 2001). Serum clearance from 1 day
and 10 day old mice were compared after a single injec-
tion with ETA. While the maximal level of toxin found in
the serum was similar for both ages, levels peaked earli-
er and were cleared earlier in the 10 day old mice, which
showed no signs of response to the toxin, as compared
to the one day old mice which began to exfoliate after 2
hours of exposure to the toxin. Therefore, ETA was not
cleared as efficiently in the one-day old mice as in the 10
day old mice. To address whether a sustained high level
of ETA would result in exfoliation, 10 day old mice were
given repeated injections of toxin so that the maximal
level of toxin was maintained for a period of time (4
hours). Exfoliation occurred in these mice confirming the
presence and accessibility of the target for ETA in this
population and the ability of the toxins to affect adults
under certain conditions. It was concluded that whereas
the adaptive immune response is not needed for protec-
tion of adult mice from SSSS, efficient clearance of the
toxin from the bloodstream is a critical factor (Plano et al,
2001). The acuteness with which the mice were no
longer susceptible to the affects of the toxin suggests
that in addition to the development of the system
required to clear the toxin (probably renal), other events,
perhaps differential expression of unidentified compo-
nents in the skin, may be contributing to the protection of
adults.
Mechanisms of action:
Exfoliative toxins as potential superantigens.
There was an ongoing debate as to whether the exfolia-
tive toxins function as superantigens that contribute to
the pathogenesis of SSSS, and there are several publi-
cations addressing this question (Bailey et al, 1995;
Monday et al, 1999; Plano et al, 2000; Vath et al, 1997).
Bacterial superantigens are a family of proteins able to
bind simultaneously to the major histocompatibility
complex class II and to the T-cell receptor (TCR), result-
ing in stimulation of a large number of T-cells expressing
specific V subsets of the T-cell repertoire (Marrack and
Kappler, 1990). This stimulation then leads to the
release of numerous cytokines and subsequent systemic
symptoms. Classic superantigen mediated diseases,
such as toxic shock syndromes, are associated with
erythematous rash, hypotension and multiorgan system
failure. Although SSSS can include erythema, fever and
purulent infective foci, these are not always present. The
controversy as to whether the ETs were superantigens
stemmed from the fact that although for over 30 years it
has been known that the ETs are responsible for exfoli-
ation/epidermolysis (Melish, 1971) in SSSS, the precise
mechanism by which this occurs was not known until
recently (Amagai et al, 2000). Although stimulation of
specific V populations of T-cells has been demonstrat-
ed (Rago et al, 2000), the SSSS generally lacks the
severe systemic symptoms associated with a superanti-
gen mediated syndrome. It is unlikely that this activity
plays a major role in the pathogenesis of SSSS but may
contribute to other disease processes. It is now general-
ly accepted that in SSSS and BI the exfoliative toxins
function as unique serine proteases that specifically
cleave desmoglein 1. 
Exfoliative toxins are unique serine proteases.
For many years the mechanism of action of the exfolia-
tive toxins was unclear, however there was mounting
indirect evidence that ETA and ETB were serine proteas-
es (Dancer et al, 1990). Both ETA and ETB share amino
acid identity with staphylococcal V8 protease (glutamyl
endopeptidase I), (26% with ETA and 31% with ETB)
and most significantly, this identity includes residues of
the V8 protease serine-histidine-aspartate catalytic triad.
This catalytic triad is a signature sequence common to
trypsin-like serine proteases. Mutant forms of ETA that
contain amino acid substitutions at any one of the
residues of the catalytic triad (S195, H72, D120, ETA
numbering) have no activity as exfoliants in the animal
model of SSSS (Prevost et al, 1992; Prevost et al, 1991).
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Both ETA and ETB have esterase activity versus a
synthetic substrate, a common property of serine
proteases (Bailey and Redpath, 1992). In addition, as
stated above, after prolonged incubation times, ETA and
ETB are able to cleave  and -melanocyte-stimulating
hormone (Rago et al, 2000). Until the recent report that
ETA cleaves desmoglein 1, the strongest evidence that
ETA and ETB are proteases came from the X-ray crystal
structures of these proteins. (Cavarelli et al, 1997;
Papageorgiou et al, 1999; Vath et al, 1999; Vath et al,
1997). Comparisons of the X-ray crystal structures of
both of these toxins as well as an inactive ETA with a
mutation at the active site serine (Ser195Ala variant)
with that of glutamyl endopeptidase I clearly demonstrate
that the ETs are members of the trypsin-like serine
protease family. The structures also show that they have
significant differences at the amino- and carboxy- termi-
ni and loop regions when compared to other like serine
proteases (Papageorgiou et al, 1999). The catalytic site
of both ETs also are very similar to those of glutamate-
specific serine proteases (V8) suggesting a similar
catalytic mechanism. However, differences in the struc-
tures show that a part of the catalytic site is in an inactive
conformation in crystalized ETA, but in an active confor-
mation in ETB. This suggests that some action is neces-
sary to put ETA into an active confirmation. It has been
postulated that this could be accomplished by the
binding of ETA to a specific target possibly involving the
unique amino-terminus (Papageorgiou et al, 1999).
Analysis of the structure of the inactive Ser195Ala
variant showed no significant perturbation at the active
site, suggesting that its loss of biological activity as an
exfoliant is attributed solely to disruption of the catalytic
serine residue (Papageorgiou et al, 1999).
Exfoliative toxins specifically cleave the cadherin
protein Dsg1 but not the closely related Dsg3. The
autoimmune condition pemphigus foleacious (PF) is
characterized by blistering in the superficial epidermis,
essentially identical to SSSS (Amagai, 1999; Mahoney et
al, 1999; Stanley, 1993). This blistering is caused by the
disruption of desmosomes after loss of function of the
cadherin protein Dsg1 because of the interaction with a
specific autoantibody to Dsg1. The desmosomal
cadherin proteins, desmogleins and desmocollins, are
the major cell adhesion molecules and Dsg1 is the
predominant desmosomal cadherin protein in the upper
epidermis of the skin while Dsg3 is found in the lower
epidermis (Wu et al, 2000). With the evidence that the
ETs appeared to be potential serine proteases, and the
knowledge that PF antibodies injected into neonatal mice
cause blistering in the superficial epidermis, like that
caused by the ETs, Amagi and coworkers reasoned that
a logical target for ETs would be Dsg1. They initially
examined skin from neonatal mice injected with ETA by
immunofluorescence using antibodies against Dsg1 and
Dsg3 as a control. They focused on the deeper layers of
the epidermis, basal and immediate suprabasal areas
that have Dsg1 and Dsg3 but do not blister. Treatment
with ETA caused significant changes in Dsg1 staining
consistent with cleavage and subsequent internalization
of the cleavage products (Amagai et al, 2000). Dsg3
staining was not affected by ETA, supporting its role in
maintaining adhesion at this level of the epidermis after
exposure to an ET, (desmoglein compensation)
(Mahoney et al, 1999). To demonstrate actual cleavage
of Dsg1 they used a human keratinocyte cell line to
express cloned mouse Dsg1 or Dsg3. They treated the
transfected cells with ETA and showed by Western blot
analysis, that only Dsg1 was cleaved. To confirm these
findings in vivo they took extracts of skin from neonatal
mice that developed blisters after injection with ETA and
showed by Western blot analysis using antibodies
against Dsg1, Dsg3 and epithelial cadherin that only
Dsg1 was cleaved. These data confirmed that treatment
with ETA resulted in Dsg1 cleavage but did not demon-
strate direct cleavage by the ET. To confirm that ETA
was directly responsible for Dsg1 cleavage they isolated
the extracellular domains of both mouse and human
Dsg1, and Dsg3 as a control, using a eukaryotic expres-
sion system to produce these protein products. Using
these purified proteins they successfully demonstrated
that ETA directly cleaved the extracellular domain of
both mouse and human Dsg1 but not Dsg3 in a dose
dependent manner. In similar experiments these investi-
gators have now demonstrated that ETB (Amagai et al,
2002) and ETD (Hanakawa et al, 2002) also specifically
cleave Dsg1 but not Dsg3 of mouse and humans. They
have also identified a single cleavage site within the
extracellular segment of Dsg1 at glutamate 381 (E381)
between extracellular cadherin domains 3 and 4. Previ-
ous studies have demonstrated that the first three extra-
cellular cadherin domains of desmoglein are needed for
calcium dependent heterophilic adhesion to the desmo-
collins (Chitaev and Troyanovsky, 1997). Cleavage at
this site, E381, would release the portion of the Dsg1
involved in this heterophilic adhesion disrupting the
desmosome. In additional experiments using immunoflu-
orescence colocalization and coimmunoprecipitation,
these investigators have also demonstrated that an
exfoliation inactive mutated ET specifically binds to Dsg1
(Hanakawa et al, 2002). These data together clearly
demonstrate that the mechanism of action of these
toxins is specific recognition and proteolytic cleavage of
the structurally critical adhesion molecule, Dsg1.
Differential diagnosis of the conditions caused by
the ETs. Distinguishing between SSSS and toxic epider-
mal necrolysis (TEN) is critical as misdiagnosis of one for
the other could lead to harmful therapies. Like SSSS,
TEN is a generalized blistering condition that can involve
erythema and skin tenderness. The blisters in TEN are
deeper in the epidermis, primarily in the basal cell layer,
and are brought on by reactions, mainly to drugs. Antibi-
otic treatment indicated for the S. aureus infection
associated with SSSS could worsen the prognosis in
TEN. A hallmark difference in these conditions is the lack
of mucous membrane involvement in SSSS. This differ-
ence along with the clinical history are usually sufficient
to make the diagnosis, although definitive diagnosis can
be made by histology from a full thickness skin biopsy.
The mechanism of action of the ETs, specific cleavage of
Dsg1, along with the distribution of this precise target
explains the clinical differences seen in SSSS versus
TEN. Desmoglein 1 is expressed in the epidermis; there-
fore, it is now clear that there is no mucous membrane
involvement in SSSS because there is no target avail-
able for the toxins to act upon.
Pemphigus foliaceus and vulgaris are blistering condi-
tions caused by reaction of auto-antibodies to Dsg1 and
Dsg3 respectively. In either of these conditions antibodies
to both desmogleins can be present and the depth of the
lesions will be affected based on the predominant
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antibodies. Therefore, PF with only antibody to Dsg1, will
look indistinguishable from SSSS by histology. Clinical
history is usually sufficient to make the diagnosis versus
SSSS. One would need to establish a history of erythe-
ma, fever and try to identify the infectious focus with S.
aureus to establish the diagnosis of SSSS. 
It was recently reported that there is differential
expression of Dsg3 in human neonatal versus adult skin
(Wu et al, 2000). These investigators reported that in the
neonate Dsg3 is expressed throughout the epidermis
while in the adult it is limited to the basal and suprabasal
layers. The knowledge of the differential expression of
Dsg1 and Dsg3 in neonatal versus adult skin can explain
the clinical finding that newborns of mothers with PF
appear to be protected against blistering from maternal
anti-Dsg1 antibodies. It has been postulated that the
presence of Dsg3 in the upper epidermis compensates
for antibody induced loss of Dsg1 function thereby
inhibiting blister formation. These facts could be confus-
ing when trying to explain the lack of desmoglein
compensation in SSSS in this same population.
Likewise, if the primary desmoglein in the adult upper
epidermis is Dsg1 why are adults not more sensitive to
the affects of these toxins? Recent studies showed that
sustained high levels of ETs were sufficient to overcome
any desmoglein compensation that protected 10 day old
mice from the affects of the ETs (Plano et al, 2001). 
The protection of adults is directly related to serum
clearance of the toxins most probably due to a maturing
renal system, but the timing of protection demonstrated
in the mouse time course (Plano et al, 2001) was
extremely acute and might not be completely explained
by a gradual maturation of the system required for clear-
ance. This is also supported by the occurrence of SSSS
in healthy adults without any renal deficiencies (Oyake et
al, 2001). This would suggest that maturation and or
expression of as yet unidentified or uncharacterized skin
components might also be contributing to the relative
protection of adults from the affects of the toxins.
Recently newly identified desmogleins were reported in
mice (Whittock, 2003). The newly identified mouse Dsg5
has significant nucleotide homology, 96%, with Dsg1 and
has identical amino acid sequence at the cleavage site of
Dsg1. No information is available at this time about
levels of expression in the adults or humans, however
given the highly conserved nature of this family of
proteins one would expect that similar proteins could be
found in human skin and might be contributing to protec-
tion in the adult. Whittock and Bower have also reported
genetic evidence for an additional desmoglein isoform
(Dsg4) in the human genome (Whittock and Bower,
2003). These data considered together supports the
need for further studying this area.
Future areas of research. One of the most signifi-
cant remaining questions and an area of potential
ongoing research is what causes these toxins to be
targeted to the skin. In 1976, Fritsch and colleagues,
using radioactive iodine labeled ET, showed that the
toxins preferentially concentrate in the skin in newborn
mice (Firtsch et al, 1976). In recent studies in our labora-
tory we have shown the presence of ETs in the skin of
both newborn susceptible species and non-susceptible
species (newborn Balb/c mice and newborn rats respec-
tively) after injection with purified toxin. This suggests
that targeting to the skin may be governed by a process
or mechanism separate from those that determine target
specificity (Plano unpublished data). The crystal struc-
ture of the ETs revealed unique areas in both the amino
and carboxy-terminal regions that could potentially play
a role in specifically targeting these toxins to the upper
epidermis.
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Update of recent studies 
In recent studies published after submission of this
manuscript, Hanakawa, et al have further characterized the 
mechanism of action of the exfoliative toxins and aspects of 
the interaction of the toxins and their targets desmoglein 1,
that  contribute  to their  specificity. They have shown  that 
not only  do the toxins recognize a specific amino acid 
sequence, they also require a  calcium dependent
conformation of desmoglein 1 for cleavage.  They showed
that exfoliative toxins could not cleave Dsg1 after
pretreatment at 56oC or at high or low pH, suggesting that a 
proper conformation was needed for cleavage.  They further
confirmed that calcium depletion of Dsg1 caused a 
conformational change that resulted in the inability of a
previously active toxin to cleave its target (Hanakawa ,
2003).  In a subsequent study they report initial kinetics with
kcat/Km values that suggest very efficient proteolysis by these 
toxins. 
 Using truncated mutant human Dsg1 and chimeric
Dsg’s generated with human Dsg1 and either human Dsg3
or canine Dsg1 they identified regions of Dsg1 upstream
from the cleavage site important for both binding and
specific cleavage by these toxins (Hanakawa  , 2004). 
These data support the complexity of the toxin target
interactions that govern the exquisite species specificity and
probably contribute to the age specificity of the syndromes
caused by these toxins and validate the importance of 
continued investigation of these unique toxins.
Hanakawa Y, Selwood T, Woo D, Lin C, Schechter NM,
Stanley JR: Calcium-dependent conformation of desmoglein 
1 is required for its cleavage by exfoliative toxin. J Invest
Dermatol 121:383-389, 2003 
Hanakawa Y, Schechter NM, Lin C, Nishifuji K, Amagai M,
Stanley JR: Enzymatic and molecular characteristics of the
efficiency and specificity of exfoliative toxin cleavage of
desmoglein 1. J Biol Chem 279:5268-5277, 2004 
et al
et al
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